$Better Therapeutics (BTTX.US)$ Click Therapeutics Accelerat...
$Better Therapeutics (BTTX.US)$ Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
4 MINUTES AGO, 8:55 AM EDT
VIA BUSINESSWIRESHARE
• Better Therapeutics assets include the first FDA-authorized prescription digital therapeutic for type 2 diabetes, AspyreRx, as well as development candidates BT-002, BT-003 and BT-004 for hypertension, hyperlipidemia, and MASH.
• Initial efforts will focus on further development of AspyreRx to adapt it for the treatment of obesity and to benefit from Click's AI-enabled platform as part of Click's obesity digital therapeutic in development, CT-181; Click does not plan to self-commercialize AspyreRx as-is at this time.
• CT-181 will be optimized for combination use with anti-obesity and diabetes medications such as GLP-1s, including current injectables and future oral formulations, with the goal of improving treatment persistence, outcomes, and value.
4 MINUTES AGO, 8:55 AM EDT
VIA BUSINESSWIRESHARE
• Better Therapeutics assets include the first FDA-authorized prescription digital therapeutic for type 2 diabetes, AspyreRx, as well as development candidates BT-002, BT-003 and BT-004 for hypertension, hyperlipidemia, and MASH.
• Initial efforts will focus on further development of AspyreRx to adapt it for the treatment of obesity and to benefit from Click's AI-enabled platform as part of Click's obesity digital therapeutic in development, CT-181; Click does not plan to self-commercialize AspyreRx as-is at this time.
• CT-181 will be optimized for combination use with anti-obesity and diabetes medications such as GLP-1s, including current injectables and future oral formulations, with the goal of improving treatment persistence, outcomes, and value.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
